AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30
Study 7864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30
Study 2606592 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 2606592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone/Timolol
Number of subjects: 0
Study 2606592 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study 2606592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1205270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpyloric tube
Number of subjects: 0
Study 1205270 — intervention group
Group type: COMPARATOR
Intervention: Ordinary solid meal
Number of subjects: 0
Study 6991659 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring alone
Number of subjects: 690
Study 6991659 — intervention group
Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 690
Study 6991659 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring with option to obtain fetal scalp pH
Number of subjects: 690
Study 30977301 — intervention group
Group type: EXPERIMENTAL
Intervention: LCIG-HV formulation
Number of subjects: 28
Study 30977301 — intervention group
Group type: COMPARATOR
Intervention: LCIG-LV formulation
Number of subjects: 28
Study 28916371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 530
Study 28916371 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 530
Study 26458906 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and tailored counseling delivered by village doctors for 5 years
Number of subjects: 2160
Study 26458906 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (no counseling for the first 5 years)
Number of subjects: 2160
Study 23650072 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9272
Number of subjects: 25
Study 23650072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21494175 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (2 doses, 6 to 9 months apart)
Number of subjects: 394
Study 21494175 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine coadministered with DTaP and Hib vaccines (2 doses of HAV vaccine, 6 to 9 months apart)
Number of subjects: 394
Study 21494175 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP and Hib vaccines followed by HAV vaccine (DTaP and Hib at 15 months, HAV 30 days later, second dose of HAV 7 to 10 months after DTaP+Hib)
Number of subjects: 394
Study 19782785 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class II
Number of subjects: 1758
Study 19782785 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers, aldosterone antagonists, CRT therapy
Number of subjects: 1758
Study 19782785 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1758
Study 17370488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6), Shenmen (HT 7), Danzhong (CV 17)
Number of subjects: 80
Study 17370488 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of amiodarone
Number of subjects: 80
Study 17370488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 15215025 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast FoamWalker boot
Number of subjects: 12
Study 15215025 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass cast
Number of subjects: 12
Study 15215025 — intervention group
Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 12
Study 11174621 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation 5 mg/d (SG)
Number of subjects: 150
Study 11174621 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (PG)
Number of subjects: 150
Study 9753804 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group 1, n = 29)
Number of subjects: 59
Study 9753804 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular narcotic injections (Group 2, n = 30)
Number of subjects: 59
Study 8154809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile sensation (TS) classified as malignant (gritty)
Number of subjects: 169
Study 8154809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile sensation (TS)
Number of subjects: 169
Study 8154809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 169
Study 8154809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TS and FNAC
Number of subjects: 169
Study 3144941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (15 mg/kg)
Number of subjects: 13
Study 3144941 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (1 g/m2 body surface area)
Number of subjects: 13
Study 3144941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sodium aurothiomalate (up to 100 mg/week)
Number of subjects: 13
Study 27521574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (80-100 mg/day)
Number of subjects: 0
Study 27521574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27521574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 30691745 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric current combined with simultaneous muscle stretching (EME technique)
Number of subjects: 48
Study 30691745 — intervention group
Group type: COMPARATOR
Intervention: Electrical current (EC) alone
Number of subjects: 48
Study 30691745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EME and EC)
Number of subjects: 48
Study 27885061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day (5 days at baseline and 3 days at Month 12)
Number of subjects: 0
Study 27885061 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a 44 µg three times/week
Number of subjects: 0
Study 26422822 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavior therapy (TD‐CBT)
Number of subjects: 290
Study 26422822 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific cognitive behavior therapy (DS‐CBT)
Number of subjects: 290
Study 23206837 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloons (PEB)
Number of subjects: 402
Study 23206837 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 402
Study 23206837 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 402
Study 21753868 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment consisting of daily pelvic floor muscle training with weekly supervision for 2 months.
Number of subjects: 14
Study 21753868 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after treatment for 2 months.
Number of subjects: 14
Study 19157574 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKnife
Number of subjects: 100
Study 19157574 — intervention group
Group type: COMPARATOR
Intervention: Bipolar dissection
Number of subjects: 100
Study 16970532 — intervention group
Group type: EXPERIMENTAL
Intervention: Johrei healing (three 20-minute sessions for 5 weeks)
Number of subjects: 21
Study 25796337 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R®II manufactured using recombinant human albumin (rHA)
Number of subjects: 0
Study 25796337 — intervention group
Group type: COMPARATOR
Intervention: M-M-R®II manufactured using human serum albumin (HSA)
Number of subjects: 0
Study 25796337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rHA and HSA formulations
Number of subjects: 0
Study 10601085 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 102
Study 10601085 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 102
Study 8936516 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline injection
Number of subjects: 20
Study 8936516 — intervention group
Group type: COMPARATOR
Intervention: sterile water injection (control)
Number of subjects: 20
Study 1750589 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl
Number of subjects: 58
Study 1750589 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural fentanyl
Number of subjects: 58
Study 6808622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (administered via metered dose aerosol at a lower dose than currently used)
Number of subjects: 10
Study 6808622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30867157 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 0
Study 30867157 — intervention group
Group type: COMPARATOR
Intervention: Standard wound management
Number of subjects: 0
Study 29678969 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of the EHR to default to a dispense quantity of 10 tablets
Number of subjects: 36
Study 29678969 — intervention group
Group type: COMPARATOR
Intervention: No EHR change (control)
Number of subjects: 36
Study 27906598 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 with oral dexamethasone 8 mg q8 hours
Number of subjects: 133
Study 27906598 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 with sustained release oral nifedipine 20 mg q8 hours
Number of subjects: 133
Study 27906598 — intervention group
Group type: COMPARATOR
Intervention: Only supplemental O2
Number of subjects: 133
Study 24587571 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 3.5 mg (ZST)
Number of subjects: 40
Study 24587571 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 40
Study 24587571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22747095 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPowerplus™ (EMP+)
Number of subjects: 10
Study 20307353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (60 g WG/d for 16 weeks)
Number of subjects: 316
Study 20307353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (60 g WG/d for 8 weeks followed by 120 g WG/d for 8 weeks)
Number of subjects: 316
Study 20307353 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary change)
Number of subjects: 316
Study 18559985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol (beta-adrenergic receptor antagonist)
Number of subjects: 0
Study 18559985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18559985 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-AR antagonist)
Number of subjects: 0
Study 15774609 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 53
Study 15774609 — intervention group
Group type: COMPARATOR
Intervention: Control (matched healthy individuals)
Number of subjects: 53
Study 12006443 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV via mouthpiece
Number of subjects: 8
Study 12006443 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV with ventilators
Number of subjects: 8
Study 12006443 — intervention group
Group type: COMPARATOR
Intervention: Unencumbered walks (breathing normally)
Number of subjects: 8
Study 12006443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-assisted walks
Number of subjects: 8
Study 10484947 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 67
Study 10484947 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 67
Study 8604368 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention control training (RCT) for younger children (aged 4 to 5 years)
Number of subjects: 30
Study 8604368 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention control training (RCT) for older children (aged 7 to 8 years)
Number of subjects: 30
Study 2008547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 112
Study 2008547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 7038977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod (daily subcutaneous injections)
Number of subjects: 73
Study 7038977 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 73
Study 7038977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 73
Study 7038977 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 73
Study 31480676 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WG) 40 g/day
Number of subjects: 37
Study 31480676 — intervention group
Group type: COMPARATOR
Intervention: Hydrolysed Collagen (CG) 38 g/day
Number of subjects: 37
Study 28864705 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity impact loading exercise
Number of subjects: 0
Study 28864705 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity resistance training
Number of subjects: 0
Study 28864705 — intervention group
Group type: COMPARATOR
Intervention: Home‐based 'positive' control group
Number of subjects: 0
Study 26765515 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (provided with activity and sleep data during each HD treatment)
Number of subjects: 29
Study 26765515 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 29
Study 26765515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking device
Number of subjects: 29
Study 25258158 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioGard Emboli Protection cannula
Number of subjects: 66
Study 25258158 — intervention group
Group type: COMPARATOR
Intervention: Standard aortic cannula
Number of subjects: 66
Study 22803426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine Injection (LI) 2 mg/kg given by intravenous dripping 30 min before autologous blood collection
Number of subjects: 60
Study 22803426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ligustrazine Injection)
Number of subjects: 60
Study 20070414 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk reports, booklets on alcohol-associated risks, and advice from physicians, followed by a health educator call
Number of subjects: 239
Study 20070414 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about alcohol-related risks
Number of subjects: 239
Study 20070414 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading through the educational booklet
Number of subjects: 239
Study 20070414 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception that physicians discussed risks and advised changing drinking behaviors
Number of subjects: 239
Study 18039195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination inhalers containing F/S
Number of subjects: 70
Study 18039195 — intervention group
Group type: COMPARATOR
Intervention: Oral or parenteral corticosteroids (7-14 days) and other medications (retrospective group)
Number of subjects: 70
Study 18039195 — intervention group
Group type: COMPARATOR
Intervention: Oral or parenteral corticosteroids (7-14 days) and other medications (prospective group)
Number of subjects: 70
Study 16145022 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy call
Number of subjects: 34
Study 16145022 — intervention group
Group type: COMPARATOR
Intervention: Light call with alcohol
Number of subjects: 34
Study 16145022 — intervention group
Group type: COMPARATOR
Intervention: Heavy call with placebo
Number of subjects: 34
Study 12098499 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture at the left foot (Bladder 67)
Number of subjects: 10
Study 12098499 — intervention group
Group type: COMPARATOR
Intervention: Dummy acupuncture (placebo stimulation)
Number of subjects: 10
Study 10407199 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlated motion in random dot kinematograms (RDK) with varying percentages of correlated moving pixels
Number of subjects: 0
Study 10407199 — intervention group
Group type: COMPARATOR
Intervention: Uncorrelated motion in random dot kinematograms (RDK)
Number of subjects: 0
Study 10407199 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent motion direction preceded by uncorrelated motion in RDKs
Number of subjects: 0
Study 1417008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 400 mg/m2
Number of subjects: 15
Study 1417008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 350 mg/m2
Number of subjects: 15
Study 1417008 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone
Number of subjects: 15
Study 3857335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning treatment
Number of subjects: 20
Study 3857335 — intervention group
Group type: COMPARATOR
Intervention: Flat plane occlusal splint treatment
Number of subjects: 20
Study 31042410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) with lymphoscintigraphy (LSG)
Number of subjects: 1198
Study 31042410 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB) without lymphoscintigraphy (LSG)
Number of subjects: 1198
Study 29861388 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg for 16 weeks
Number of subjects: 42
Study 29861388 — intervention group
Group type: COMPARATOR
Intervention: Control (matched participants without MC4R mutation)
Number of subjects: 42
Study 29861388 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 42
Study 26596899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG; boxing game on Xbox Kinect 360)
Number of subjects: 24
Study 26596899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; cycling)
Number of subjects: 24
Study 26596899 — intervention group
Group type: COMPARATOR
Intervention: Passive Video Game (PVG; boxing game on Xbox 360)
Number of subjects: 24
Study 26596899 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; sitting)
Number of subjects: 24
Study 26596899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24
Study 26596899 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 24
Study 26596899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger and satiety measures
Number of subjects: 24
Study 26061836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone positioning system dispatching trained lay volunteers to patients nearby (intervention group)
Number of subjects: 9828
Study 26061836 — intervention group
Group type: COMPARATOR
Intervention: No dispatch of trained lay volunteers (control group)
Number of subjects: 9828
Study 23756654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 439
Study 23756654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise
Number of subjects: 439
Study 23756654 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study 21535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Audilex training (n = 11)
Number of subjects: 22
Study 21535135 — intervention group
Group type: COMPARATOR
Intervention: Control game playing (n = 11)
Number of subjects: 22
Study 21535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Audilex
Number of subjects: 22
Study 21535135 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 19061675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha plus ribavirin (peg‐IFNalpha/RBV) treatment for 48 weeks
Number of subjects: 47
Study 19061675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 17333800 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter without traction
Number of subjects: 258
Study 17333800 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter with traction
Number of subjects: 258
Study 17333800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal tablets
Number of subjects: 258
Study 15692263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet (MD)
Number of subjects: 21
Study 15692263 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation with MD
Number of subjects: 21
Study 15692263 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation with both diets
Number of subjects: 21
Study 15692263 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 21
Study 10725066 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leucocytapheresis (LCP)
Number of subjects: 25
Study 9452848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine (40 mg)
Number of subjects: 40
Study 9452848 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (2 ml 0.5%)
Number of subjects: 40
Study 7639022 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous ketamine
Number of subjects: 0
Study 7639022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 0
Study 7639022 — intervention group
Group type: COMPARATOR
Intervention: Conventional anaesthesia (halothane, nitrous oxide, and relaxant)
Number of subjects: 0
Study 3286166 — intervention group
Group type: COMPARATOR
Intervention: Constant insulin infusion (0.175 mU/kg.min)
Number of subjects: 7
Study 3286166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin delivery (2.1 mU/kg at 12-min intervals)
Number of subjects: 7
Study 3286166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both constant and pulsatile insulin delivery
Number of subjects: 7
Study 28867520 — intervention group
Group type: EXPERIMENTAL
Intervention: iAssist guidance system
Number of subjects: 50
Study 28867520 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 50
Study 24721637 — intervention group
Group type: COMPARATOR
Intervention: 1-day Acuvue(®) clear SCL
Number of subjects: 16
Study 24721637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day Acuvue(®) Define(TM) tinted SCL
Number of subjects: 16
Study 23817279 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional expression influenced by time of day (RR = 1.05) and impaired mobility (RR = 1.37)
Number of subjects: 30